The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Myasthenia gravis: past, present, and future
Open accessAbstract
Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuromuscular junction (NMJ). These proteins include the nicotinic AChR or, less frequently, a muscle-specific tyrosine kinase (MuSK) involved in AChR clustering. Much is known about the mechanisms that maintain self tolerance and modulate anti-AChR Ab synthesis, AChR clustering, and AChR function as well as those that cause neuromuscular transmission failure upon Ab binding. This insight has led to the development of improved diagnostic methods and to the design of specific immunosuppressive or immunomodulatory treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oosterhuis, H. (1997) · Cited by 2,397
Myasthenia gravis: Recommendations for clinical research standards
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000) · Neurology · doi:10.1212/wnl.55.1.16 · Cited by 1,651
Self-citationAcetylcholinesterase — new roles for an old actor
Soreq, H., & Seidman, S. (2001) · Nature Reviews Neuroscience · doi:10.1038/35067589 · Cited by 1,390
Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001) · Nature Medicine · doi:10.1038/85520 · Cited by 1,183
Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor
Samuelsson, A., Towers, T. L., & Ravetch, J. V. (2001) · Science · doi:10.1126/science.291.5503.484 · Cited by 1,053
Autoimmune Response to Acetylcholine Receptor
Patrick, J., & Lindstrom, J. (1973) · Science · doi:10.1126/science.180.4088.871 · Cited by 1,043
Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells
Weiner, H. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820117.x · Cited by 846
Myasthenia gravis: recommendations for clinical research standards
Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J. C., Penn, A. S., & Sanders, D. B. (2000) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)01595-2 · Cited by 648
Self-citationRituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 625
Myasthenia Gravis: A New Hypothesis
Simpson, J. A. (1960) · Scottish Medical Journal · doi:10.1177/003693306000501001 · Cited by 583
Gronseth, G. S., & Barohn, R. J. (2000) · Neurology · doi:10.1212/wnl.55.1.7 · Cited by 576
A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis
Palace, J., Newsom-Davis, J., Lecky, B., & Myasthenia Gravis Study Group (1998) · Neurology · doi:10.1212/wnl.50.6.1778 · Cited by 473
Myasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate Degradation
Drachman, D. B., Angus, C. W., Adams, R. N., Michelson, J. D., & Hoffman, G. J. (1978) · New England Journal of Medicine · doi:10.1056/nejm197805182982004 · Cited by 437
Balandina, A., Lécart, S., Dartevelle, P., Saoudi, A., & Berrih-Aknin, S. (2005) · Blood · doi:10.1182/blood-2003-11-3900 · Cited by 429
Tindall, R. S. A., Rollins, J. A., Phillips, J. T., Greenlee, R. G., Wells, L., & Belendiuk, G. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703193161205 · Cited by 394
Clinical evaluation and management of myasthenia gravis
Keesey, J. C. (2004) · Muscle & Nerve · doi:10.1002/mus.20030 · Cited by 285
Fitch, J. C. K., Rollins, S., Matis, L., Alford, B., Aranki, S., Collard, C. D., Dewar, M., Elefteriades, J., Hines, R., Kopf, G., et al. (1999) · Circulation · doi:10.1161/01.cir.100.25.2499 · Cited by 281
Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
Chaudhry, V., Cornblath, D. R., Griffin, J. W., O’Brien, R., & Drachman, D. B. (2001) · Neurology · doi:10.1212/wnl.56.1.94 · Cited by 259
SAHASHI, K. O., ENGEL, A. G., LAMBERT, E. H., & HOWARD, F. M. (1980) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198003000-00005 · Cited by 227
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues.
Meri, S., Waldmann, H., & Lachmann, P. J. (1991) · PubMed · Cited by 196
Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction
Ruegg, M. A., & Bixby, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01154-5 · Cited by 189
Natural killer cells determine the outcome of B cell–mediated autoimmunity
Shi, F.-D., Wang, H.-B., Li, H., Hong, S., Taniguchi, M., Link, H., Kaer, L. V., & Ljunggren, H.-G. (2000) · Nature Immunology · doi:10.1038/79792 · Cited by 187
Striational Antibodies in Myasthenia Gravis
Romi, F. R., SKEIE, G. O., Gilhus, N. E., & Aarli, J. A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.442 · Cited by 175
Wood, S. J., & Slater, C. R. (1997) · The Journal of Physiology · doi:10.1113/jphysiol.1997.sp022007 · Cited by 174
Guidelines in electrodiagnostic medicine
American Association Of Electrodiagnostic Medicine (1992) · Muscle & Nerve · doi:10.1002/mus.880150218 · Cited by 167
Molecular architecture of the neuromuscular junction
Hughes, B. W., Kusner, L. L., & Kaminski, H. J. (2006) · Muscle & Nerve · doi:10.1002/mus.20440 · Cited by 165
Self-citationVincent, A. C., & Leite, M. I. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000180660.57801.3f · Cited by 150
Liu, R., Cava, A. L., Bai, X., Jee, Y., Price, M. A., Campagnolo, D. I., Christadoss, P., Vollmer, T. L., Kaer, L. V., & Shi, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.7898 · Cited by 141
Delpy, L., Douin‐Echinard, V., Garidou, L., Bruand, C., Saoudi, A., & Guéry, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5050 · Cited by 130
The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis
Brenner, T., Hamra‐Amitay, Y., Evron, T., Boneva, N., Seidman, S., & Soreq, H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0609com · Cited by 129
Keshavjee, S. H., Davis, R. D., Zamora, M. R., de Perrot, M. E., & Patterson, G. A. (2005) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.06.048 · Cited by 120
Biesecker, G., & Gomez, C. M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.8.2654 · Cited by 119
C5 gene influences the development of murine myasthenia gravis.
Christadoss, P. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.8.2589 · Cited by 112
Deng, C., Goluszko, E., Tüzün, E., Yang, H., & Christadoss, P. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.2.1077 · Cited by 110
Cytokine-modulated Regulation of Helper T Cell Populations
Yates, A. J., Bergmann, C. C., van Hemmen, J. L., STARK, J., & Callard, R. E. (2000) · Journal of Theoretical Biology · doi:10.1006/jtbi.2000.2147 · Cited by 104
Induction of HLA-DR expression on human myoblasts with interferon-gamma.
Hohlfeld, R., & Engel, A. G. (1990) · Europe PMC (PubMed Central) · Cited by 95
Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis
Feferman, T., Maiti, P. K., Berrih‐Aknin, S., Bismuth, J., Bidault, J., Fuchs, S., & Souroujon, M. C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5324 · Cited by 93
Absence of IFN-γ or IL-12 Has Different Effects on Experimental Myasthenia Gravis in C57BL/6 Mice
Karachunski, P. I., Ostlie, N. S., Monfardini, C., & Conti‐Fine, B. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5236 · Cited by 86
Self-citationBalasa, B., Deng, C., Lee, J., Christadoss, P., & Sarvetnick, N. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2856 · Cited by 70
Yi, Q., Åhlberg, R., Pirskanen, R., & Lefvert, A. K. (1994) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)90044-2 · Cited by 63
Im, S., Barchan, D., Maiti, P. K., Raveh, L., Souroujon, M. C., & Fuchs, S. (2001) · The FASEB Journal · doi:10.1096/fj.01-0072com · Cited by 57
Wang, Z.-Y., Okita, D. K., Howard, J. F., et al. (1998) · Neurology · doi:10.1212/wnl.50.4.1045 · Cited by 57
Major pathogenic effects of anti-MuSK antibodies in Myasthenia Gravis
Boneva, N., Frenkian, M., Bidault, J., Brenner, T., & Berrih‐Aknin, S. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.05.017 · Cited by 49
Christadoss, P., & Goluszko, E. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00473-8 · Cited by 46
Glass, D. J., DeChiara, T. M., Stitt, T. N., DiStefano, P. S., Valenzuela, D. M., & Yancopoulos, G. D. (1996) · PubMed · Cited by 41
Duan, R., Adikari, S. B., Huang, Y.-M., Link, H., & Xiao, B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.03.017 · Cited by 37
Goluszko, E., Deng, C., Poussin, M., & Christadoss, P. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00474-x · Cited by 36
Single-channel basis of slow inactivation of Na+ channels in rat skeletal muscle
Ruff, R. L. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.271.3.c971 · Cited by 35
Wang, H., Li, H., Shi, F., Chambers, B. J., Link, H., & Ljunggren, H. (2000) · International Immunology · doi:10.1093/intimm/12.10.1381 · Cited by 31
Steroids have an important role
Bedlack, R., & Sanders, D. B. (2001) · Muscle & Nerve · doi:10.1002/mus.1221 · Cited by 25
Mycophenolate mofetil and myasthenia gravis
Ciafaloni, E. (2005) · Lupus · doi:10.1191/0961203305lu2118oa · Cited by 19
Prospects for a T-cell receptor vaccination against myasthenia gravis
Cohen‐Kaminsky, S., & Jambou, F. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.4.473 · Cited by 14
Cited by
Kamisawa, T., Zen, Y., Pillai, S., & Stone, J. H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60720-0 · Cited by 1,212
Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis
Hughes, E. G., Peng, X., Gleichman, A. J., Lai, M., Zhou, L., Tsou, R., Parsons, T. D., Lynch, D. R., Dalmau, J., & Balice-Gordon, R. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0167-10.2010 · Cited by 1,143
Mechanisms of Autoantibody-Induced Pathology
Ludwig, R. J., Vanhoorelbeke, K., Leypoldt, F., Kaya, Z., Bieber, K., McLachlan, S. M., Komorowski, L., Luo, J., Cabral-Marques, O., Hammers, C. M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00603 · Cited by 469
Mahajan, V. S., Mattoo, H., Deshpande, V., Pillai, S. S., & Stone, J. H. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104708 · Cited by 366
Muscle and neuronal nicotinic acetylcholine receptors: Structure, function and pathogenicity
Kalamida, D., Poulas, K., Avramopoulou, V., Fostieri, E., Lagoumintzis, G., Lazaridis, K., Sideri, A., Zouridakis, M., & Tzartos, S. J. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05935.x · Cited by 333
Metadata
- Authors
- Conti-Fine, B. M., Milani, M., & Kaminski, H. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-11-01
- Volume
- 116
- Issue
- 11
- Pages
- 2843-2854
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1983404333
- Cited by
- 691
- References
- 52
- FWCI
- 20.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.